Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients | Alcon | Completed | Travoprost 0.004% | 1 | C-12-009 | KKESH |
| "An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children ≤ 5 Years of Age with Hypophosphatasia (HPP). " | Alexion | Completed | Asfotase Alfa | 2 | ENB-010-10 | KFSH & RC-R |
| An open-Label, multicenter, expanded access study of Everolimus in Patients with advanced Nerouendocrine tumors. | Novartis | Completed | Everolimus | 3b | CRAD001K24133 | KFSH & RC-R |
| An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I) | AbbVie | Ongoing | ABT-450/r/ABT-267+ABT-333 (-/+) Ribavirin (RBV) | 3b | M14-423 | KKUH |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2) | Albireo | Ongoing | A4250 | 3 | A4250-008 | KFSH&RC-R |
| "An open-label extension study of the long-term safety, tolerability and efficacy of Ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension(CTEPH)." | GSK | Completed | Ambrisentan | 3 | 116457 | KFMC |
| AN OPEN LABEL, SINGLE ARM, MULTICENTER,SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT | Roche | Completed | Atezolizumab (MPDL3280A; RO5541267) | 3 | MO29983 | KFSH & RC-R |
| An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency | Synageva | Completed | Sebelipase alfa (SBC-102) | 2 | LAL-CL03 | KFSH & RC-R |
| "An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure " | AstraZeneca | Completed | Dapagliflozin | 3 | D169CC00001 | KKUH |
| An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care | GDRS (MOH) | Ongoing | Hydroxychloroquine sulphate | 3 | version 8 | QCH |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.